CE
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Infant exposure to Fluvoxamine through placenta and human milk : a case series - A contribution from the ConcePTION project | Frontiers in psychiatry |  | 2023 | 3 | 0 | ||
| Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema | Obesity facts | | 2022 | 53 | 125 | ||
| Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity | Frontiers in psychiatry | | 2022 | 22 | 9 | ||
| Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study | Pharmacopsychiatry | | 2021 | 62 | 224 | ||
| Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass | Obesity Surgery |  | 2020 | 209 | 1 | ||
| A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk | British Journal of Clinical Pharmacology | | 2020 | 387 | 2 | ||
| Genetic and clinic predictors of new onset diabetes mellitus after transplantation | The Pharmacogenomics Journal | 2019 | 308 | 0 | |||
| Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients | American Journal of Transplantation | | 2019 | 381 | 0 | ||
| Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study | Mayo Clinic Proceedings | | 2018 | 408 | 1 | ||
| Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances | Frontiers in Psychiatry | | 2018 | 397 | 148 | ||
| N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis | Schizophrenia bulletin | | 2018 | 52 | 6 | ||
| Association of genetic risk scores with body mass index in Swiss psychiatric cohorts | Pharmacogenetics and genomics | | 2016 | 481 | 0 | ||
| Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l'évaluation de la balance bénéfice-risque | Revue médicale suisse | | 2016 | 616 | 5 | ||
| Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments | Journal of clinical psychopharmacology | | 2015 | 527 | 1 | ||
| Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments | Pharmacogenetics and genomics | | 2015 | 582 | 0 | ||
| Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions | Hypertension | | 2015 | 510 | 1 | ||
| Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression | PloS one | | 2015 | 544 | 184 | ||
| Blood pressure in relation to coffee and caffeine consumption | Current hypertension reports | | 2014 | 527 | 1 | ||
| Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance | British journal of clinical pharmacology | | 2014 | 506 | 0 | ||
| Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women | Antiviral therapy | | 2013 | 522 | 0 | ||
| Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population | JAMA psychiatry | | 2013 | 591 | 0 | ||
| Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension | Human molecular genetics | | 2012 | 696 | 2 | ||
| Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring | Journal of chromatography. B | | 2011 | 654 | 2 | ||
| The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution | Expert opinion on drug metabolism & toxicology | | 2010 | 587 | 0 | ||
| The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone | British journal of pharmacology | | 2010 | 677 | 2 | ||
| Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety | British journal of pharmacology | | 2010 | 545 | 1 | ||
| Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study | European journal of clinical pharmacology | | 2009 | 644 | 241 | ||
| Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS | Journal of pharmaceutical and biomedical analysis | | 2009 | 620 | 0 | ||
| Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples | Journal of chromatography. B | | 2009 | 539 | 0 | ||
| Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals | Clinical pharmacology and therapeutics | | 2009 | 593 | 0 | ||
| Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizer: Evidence of a safer cardiac profile of (R)-methadone | Pharmacopsychiatry | | 2008 | 596 | 0 | ||
| CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response | Therapeutic drug monitoring | | 2008 | 669 | 0 | ||
| Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit | European journal of medical research | 2008 | 433 | 0 | |||
| Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives | Revue médicale suisse | | 2008 | 714 | 323 |
